4-(3-methyl-pyridin-2-yloxy)-cyclohexanone | 1252607-30-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(3-methyl-pyridin-2-yloxy)-cyclohexanone
• 英文别名: 4-(3-methylpyridin-2-yl)oxycyclohexan-1-one
• CAS: 1252607-30-9
• 化学式: C₁₂H₁₅NO₂
• 分子量: 205.257
• InChiKey: IUBJPGKNMZVWGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-methyl-pyridin-2-yloxy)-cyclohexanone 、 N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide 生成 N-({1-[4-(3-methyl-pyridin-2-yloxy)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide
  参考文献：
  名称：

  4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2

  摘要：

  本发明涉及式（I）化合物，其中：X、R1、R2、R3和R4如规范中所定义。本发明还涉及一种预防、治疗或改善综合症、障碍或疾病的方法，所述综合症、障碍或疾病为2型糖尿病、肥胖症和哮喘。本发明还涉及通过给哺乳动物施加至少一种式（I）化合物的治疗有效剂量来抑制CCR2活性的方法。

  公开号：

  US08324186B2

文献信息

• 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100267668A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I). wherein: X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：X、R1、R2、R3和R4如规范中所定义。该发明还包括一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病是II型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用至少一种式(I)化合物的治疗有效量来抑制CCR2活性的方法。
• US8324186B2
  申请人：——

  公开号：US8324186B2

  公开（公告）日：2012-12-04
• [EN] 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2<br/>[FR] ANTAGONISTES DE CCR2 À BASE DE 4-AZÉTIDINYL-1-HÉTÉROATOME-CYCLOHEXANE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010121036A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I). wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).